These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 3876122)

  • 21. Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.
    Pérez-Rodríguez A; García-Rivero A; Lourés E; López-Fernández MF; Rodríguez-Trillo A; Batlle J
    Haematologica; 2009 May; 94(5):679-86. PubMed ID: 19286880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of inhibitors in acquired von Willebrand syndrome.
    Mohri H; Motomura S; Kanamori H; Matsuzaki M; Watanabe S; Maruta A; Kodama F; Okubo T
    Blood; 1998 May; 91(10):3623-9. PubMed ID: 9572997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of desmopressin on von Willebrand factor multimers in Doberman Pinschers with type 1 von Willebrand disease.
    Callan MB; Giger U; Catalfamo JL
    Am J Vet Res; 2005 May; 66(5):861-7. PubMed ID: 15938072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo experiments indicate that relatively high platelet deposition in von Willebrand's disease 'Vicenza' is caused by normal platelet-VWF levels rather than by high VWF-multimers in plasma.
    d'Alessio PA; Castaman G; Rodeghiero F; de Boer HC; Federici AB; Mannucci PM; de Groot PG; Sixma JJ; Zwaginga JJ
    Thromb Res; 1992 Jan; 65(2):221-8. PubMed ID: 1579897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet--von Willebrand factor interactions in type IIB von Willebrand's disease.
    Holmberg L; Kristoffersson AC; Lamme S; Nilsson IM; Awidi A; Solum NO
    Scand J Haematol; 1985 Sep; 35(3):305-14. PubMed ID: 3877338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors.
    Casonato A; Pontara E; Bertomoro A; Dannhauser D; Secchiero S; Zaninotto M; Girolami A
    Ann Hematol; 1995 Oct; 71(4):189-94. PubMed ID: 7578526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of a case of subtype IIC von Willebrand disease: characterization of the variability of this subtype.
    Mazurier C; Mannucci PM; Parquet-Gernez A; Goudemand M; Meyer D
    Am J Hematol; 1986 Jul; 22(3):301-11. PubMed ID: 3087159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.
    Casonato A; Pontara E; Sartorello F; Bertomoro A; Durante C; Girolami A
    J Lab Clin Med; 2001 Jan; 137(1):70-6. PubMed ID: 11150026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of a bleeding tendency in severe acquired von Willebrand's disease. The role of platelet von Willebrand factor in maintaining normal hemostasis.
    Drouin J; Lillicrap DP; Izaguirre CA; Sutherland M; Windsor S; Benford K; Hoogendorn H; Giles AR
    Am J Clin Pathol; 1989 Oct; 92(4):471-8. PubMed ID: 2508465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type IC).
    Ciavarella G; Ciavarella N; Antoncecchi S; De Mattia D; Ranieri P; Dent J; Zimmerman TS; Ruggeri ZM
    Blood; 1985 Dec; 66(6):1423-9. PubMed ID: 3877533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DDAVP treatment in a child with von Willebrand disease type 2M.
    Mauz-Körholz C; Budde U; Körholz D; Göbel U
    Eur J Pediatr; 1999 Dec; 158 Suppl 3():S174-6. PubMed ID: 10650863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The von Willebrand factor.
    Rodeghiero F; Castaman G
    Ric Clin Lab; 1990; 20(2):143-53. PubMed ID: 2196663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A variant of type II von Willebrand disease with an abnormal triplet structure and discordant effects of protease inhibitors on plasma and platelet von Willebrand factor structure.
    Gralnick HR; Williams SB; McKeown LP; Maisonneuve P; Jenneau C; Sultan Y
    Am J Hematol; 1987 Mar; 24(3):259-66. PubMed ID: 3493688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New variant of von Willebrand disease type II with markedly increased levels of von Willebrand factor antigen and dominant mode of inheritance: von Willebrand disease type IIC Miami.
    Ledford MR; Rabinowitz I; Sadler JE; Kent JW; Civantos F
    Blood; 1993 Jul; 82(1):169-75. PubMed ID: 8324222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New families with von Willebrand disease type 2M (Vicenza).
    Zieger B; Budde U; Jessat U; Zimmermann R; Simon M; Kätzel R; Sutor AH
    Thromb Res; 1997 Jul; 87(1):57-64. PubMed ID: 9253800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand's disease with low platelet von Willebrand factor content.
    Casonato A; Sartori MT; Pontara E; Zucchetto A; Dannhäuser D; Patrassi G; Girolami A
    Blood Coagul Fibrinolysis; 1992 Apr; 3(2):149-53. PubMed ID: 1606286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Type 2B von Willebrand's disease due to Val1316Met mutation. Heterogeneity in the same sibship.
    Rendal E; Penas N; Larrabeiti B; Pérez A; Vale A; López-Fernández MF; Batlle J
    Ann Hematol; 2001 Jun; 80(6):354-60. PubMed ID: 11475150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.